2016 年第 5 期 第 14 卷

紫杉醇联合顺铂与替吉奥联合顺铂治疗中晚期非小细胞肺癌的疗效对比研究

作者：

单位：

关键词：紫杉醇替吉奥顺铂中晚期非小细胞肺癌

• 摘要：
• 【摘要】【摘要】目的：对比分析中晚期肺癌治疗中紫杉醇与替吉奥分别联合顺铂的治疗方案应用效果差异。方法：将就诊于我院的82例中晚期非小细胞肺癌作为观察对象，并随机分为两组。对照组采用紫杉醇联合顺铂治疗，观察组采用替吉奥联合顺铂治疗。对比两组近期疗效、远期疗效及副作用发生率。结果：经过4个月的治疗后，对照组治疗总有效率为19.51%，而观察组治疗总有效率为41.46%，观察组明显高于对照组（P<0.05）,且有统计学差异。随访结果显示，对照组中位生存期及中位无进展分别为10.83月及8.28月，观察组中位生存期及中位无进展分别为13.31月及9.11月，观察组中位生存期及中位无进展均明显高于对照组（P<0.05）, 且有统计学差异。此外，两组4个疗程治疗时间内副作用发生率比较无统计学差异（P>0.05)。结论：替吉奥联合顺铂治疗中晚期非小细胞肺癌比紫杉醇联合顺铂治疗方案可有效提高临床治疗效果及随访生存期，且未新增明显副反应。
• 【Abstract】Objective: Analysis curative effect of paclitaxel combined cisplatin and gonow combined cisplatin in middle-late stage lung cancer. Methods: 82 cases of middle-late stage lung cancer in our hospital were as research object, and randomly divided into two groups. Control group treated with paclitaxel combined cisplatin, observation group treated with gonow combined cisplatin. Contrast long curative effect in two groups in the near future curative effect, and the incidence of side effects. Results: After four months course of treatment, the total effective rate of control group was 19.51%, and the total effective rate of observation group was 41.46%. observation group was higher than control group(P<0.05). In the follow-up period，observation group was higher than control group(P<0.05). In addition, four courses of treatment time, There was no statistical difference of side effect between two groups(P>0.05). Conclusion: Joint for gonow and cisplatin in the treatment of middle-late stage lung cancer treatment can effectively improve the effect of clinical oncology and followed for survival.